EDSA is the ticker symbol for Edesa Biotech, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks EDSA with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is EDSA a good stock to buy?

EDSA is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/EDSA.

Where does 13F Pro source EDSA data?

All Edesa Biotech, Inc. fundamentals and ownership data come directly from SEC EDGAR. Edesa Biotech, Inc. files with the SEC under CIK 1540159. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Edesa Biotech, Inc.(EDSA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Edesa Biotech, Inc. (EDSA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. EDSA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.3m in revenue and is scored on the micro-cap board instead. Top institutional holders of EDSA by reported 13-F value include Velan Capital Investment Management, Rubric Capital Management, PERCEPTIVE ADVISORS, based on the most recent SEC filings. EDSA trades on the Nasdaq exchange and files with the SEC under CIK 1540159. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EDSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edesa Biotech, Inc. directly from SEC EDGAR.

Net Income

$-5.4M

EDSA key financials by period

Edesa Biotech, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2022	10-K	$780.0K	$-17.5M	—
FY 2020	10-K	$328.8K	$-6.4M	—
FY 2018	10-K	$211.8K	$-5.0M	—
FY 2017	10-K	$228.3K	$-5.0M	—
FY 2016	10-K	$1.3M	$-5.0M	—
FY 2015	10-K	$758.7K	$-2.8M	—

Institutions holding EDSA

Institutional investors reporting a position in Edesa Biotech, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Velan Capital Investment Management	827,500	$6.7M	2026-06-30
Rubric Capital Management	669,500	$5.4M	2026-06-30
PERCEPTIVE ADVISORS	563,239	$4.6M	2026-06-30
MILLENNIUM MANAGEMENT	561,751	$4.6M	2026-06-30
Stonepine Capital Management	456,439	$3.2M	2026-06-30
Boxer Capital Management	205,000	$1.7M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	81,839	$665.4K	2026-06-30
GEODE CAPITAL MANAGEMENT	80,879	$657.6K	2026-06-30
JANE STREET GROUP	72,465	$589.1K	2026-06-30
VANGUARD FIDUCIARY	38,718	$314.8K	2026-06-30

SEC EDGAR: CIK 1540159 →

Edesa Biotech, Inc.

EDSA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.